19 results about "Trastuzumab" patented technology

The invention belongs to the technical field of biological medicines, and particularly relates to an iron-based nano material, a preparation method and application of the iron-based nano material in preparation of medicines for treating breast cancer. The iron-based nano material is formed by loading a ferroptosis inducer on a nano carrier; the nano carrier is an iron-based metal organic framework material Fe-MOF (Metal Organic Framework). A product FEH for treating breast cancer is obtained based on coupling of the iron-based nano-material provided by the invention with a targeted drug such as trastuzumab. The FEH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of trastuzumab and ferroptosis combined anti-tumor. As a safe and effective tumor treatment strategy, the EFH has huge clinical transformation potential.

The invention belongs to the technical field of biological medicines, and particularly relates to a ferrozirconium bimetallic nano-material, a preparation method and application of the ferrozirconium bimetallic nano-material in preparation of medicines for treating breast cancer. The ferrozirconium bimetallic nano material is formed by loading a CDK4 / 6 inhibitor on a nano carrier; wherein the nano carrier is an organic framework material Zr-Fe MOF containing double metals of Zr and Fe, and the CDK4 / 6 inhibitor is preferably ribociclib. A product ZFRH for treating breast cancer is obtained based on coupling of the ferrozirconium bimetallic nano-material provided by the invention with a targeted drug such as trastuzumab. The ZFRH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of combined anti-tumor of trastuzumab and a CDK4 / 6 inhibitor. As a safe and effective tumor treatment strategy, the ZFRH has huge clinical transformation potential.

Abstract Disclosed herein are Trastuzunab-linked TLR-agonist derivative analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The Trastuzunab-linked TLR-agonist derivative analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and / or hydroxylamine group. Also disclosed herein are non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such Trastuzumab-linked TLR-agonist derivative analogs. Typically, the modified Trastuzunab- linked TLR-agonist derivative analogs include at least one oxime, carbonyl, dicarbonyl, and / or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs and modified non-natural amino acid Trastuzumab-linked TLR-agonist derivative analogs, including therapeutic, diagnostic, and other biotechnology use. Abstract 20 26 20 50 50 29 J un 2 02 6 A b s t r a c t 2 0 2 6 2 0 5 0 5 0 2 9 J u n 2 0 2 6

The invention belongs to the technical field of biological medicines, and particularly relates to a combined therapy of detrastuzumab and TCR-T in solid tumors. The invention relates to application of detrastuzumab combined with TCR-T cells in preparation of drugs for treating solid tumors. According to the present invention, based on the drug action mechanism, in combination with clinical patient specimen data and single cell sequencing analysis, a variety of cytobiology and molecular biology means are adopted, and through a variety of in-vivo and in-vitro models, the macroscopic to microscopic deep research is performed; the application of TCR-T and T-DXd in solid tumors is comprehensively and systematically researched, the research process has very strong technical comprehensiveness, and the synergistic effect of T-DXd combined with TCR-T is found from the research process. At present, T-DXd is already marketed and applied clinically, and TCR-T is proved to have better safety, so that a T-DXd and TCR-T duplex strategy has a very good clinical transformation prospect, and the combination of precision medicine and transformation medicine is reflected.

The present invention provides an antibody drug conjugate composed of an anti-HER2 trastuzumab monoclonal antibody and an iridium(III) N-heterocyclic carbene (NHC) complex connected with a cathepsin B-cleavable GGFG tetrapeptide linker, a method of preparing the same and a method of using the same for anticancer treatment. The provided antibody drug conjugate has improved tumor target specificity and delivery.

The present invention relates to a HER2-targeted antibody-coupled gold (III) porphyrin drug, a synthesis method thereof, and tumor treatment applications. The HER2-targeted antibody-coupled gold (III) porphyrin drug of the present invention is formed by connecting anti-HER‑2 trastuzumab and an A3B-type gold (III) porphyrin complex via a connector, wherein the connector includes a maleimide linker connected to the antibody and a self-eliminating linker connected to the A3B-type gold (III) porphyrin complex. The present invention combines an A3B-type gold (III) porphyrin complex with anti-tumor activity with trastuzumab with a specific recognition function as a carrier, utilizes antibodies to accurately strike tumor cells, delivers the drug to the tumor environment, improves the tumor targeting of the gold (III) porphyrin complex, and achieves precision treatment. Not only can the distribution of the drug in the body be improved, but also the accumulation in non-tumor sites can be reduced, the amount of metal complex used can be reduced, and toxic side effects can be reduced; it can also achieve efficient delivery of gold drugs to tumor tissues, thereby improving the effect of cancer treatment.

A system for treating cancer is disclosed. According to an embodiment of the present invention, the system comprises: an electric field applying device for applying an electric field for tumor treatment; and a delivery system for delivering an antibody-conjugated drug; the antibody coupling drug is selected from one of a group consisting of a group consisting of Wei Dicetuzumab, a group consisting of detrastuzumab, a group consisting of enmetrastuzumab, DP-303c, a group consisting of SHR-A1811, SYD985, a group consisting of LCB14-0110, a group consisting of BDC-1001, a group consisting of BB-1701, a group consisting of TAA013 and a group consisting of A166. According to the system provided by the embodiment of the invention, non-small cell lung cancer cell proliferation can be inhibited.

This invention relates to an immunoliposome containing tebuconazole, its preparation method, and its application in anti-breast cancer treatment. The tebuconazole immunoliposome is composed of tebuconazole coated with phospholipids and cholesterol, and modified with trastuzumab. The preparation method of the tebuconazole immunoliposome of this invention is simple and exhibits excellent anti-tumor effects. The novel tebuconazole immunoliposome can overcome the drawback of tebuconazole's non-selectivity for tumor cells, thus enhancing its anti-tumor efficacy. Furthermore, the actively targeted immunoliposome with trastuzumab as a target exhibits significant targeting in vivo, and its anti-tumor effect is significantly different from that of non-targeted liposomes. This invention provides a new avenue for the anti-tumor application of tebuconazole and is of great significance for advancing the clinical application of tebuconazole.

The invention relates to the field of biological medicine, and discloses a metering system and method of trastuzumab for injection, and the method comprises the following steps: establishing a patient information base, collecting basic information, disease information, basic disease information and previous treatment history information data of a patient, planning an initial administration scheme according to the patient information base, the method comprises the following steps: monitoring the blood concentration of a patient, the left ventricular ejection fraction and the data of the adverse reaction condition of the patient in real time, determining whether to pause the administration, adjust the single administration amount and send out early warning information according to the monitoring result, collecting the data of the remaining amount, the storage time and the storage condition of the remaining drug in real time, and judging whether the remaining drug can be reused according to the data of the remaining drug. And according to a judgment result, planning a processing flow of the residual medicine. Multi-dimensional information of a patient is comprehensively collected, comprehensive judgment is carried out in combination with diseases and physical conditions of the patient, the administration frequency is reasonably planned, the single-time administration amount is adjusted, residual drugs are properly managed, and the metering process of trastuzumab is optimized.

The application discloses a cell culture method for producing trastuzumab, which can effectively reduce the acid peak of the antibody, improve the main peak of CE-SDS of the antibody, and reduce G0F and other glycosylation modifications without changing other key quality attributes of trastuzumab by adjusting the components of the feed and the culture temperature. The culture method is simple in operation and suitable for large-scale production.

The invention belongs to the technical field of biological medicines, and particularly relates to a zirconium-copper bimetallic nano-material, a preparation method and application of the zirconium-copper bimetallic nano-material in preparation of medicines for treating breast cancer. The zirconium-copper bimetallic nano-material is formed by loading an oxidative stress inducer on a nano-carrier, wherein the nano carrier is an organic framework material Zr-Cu MOF (Metal Organic Framework) containing double metals of Zr and Cu, and the oxidative stress inducer is optimally Elesclomol. A product, namely ZCEH, for treating breast cancer is obtained based on coupling of the zirconium-copper bimetallic nano-material with a targeted drug such as trastuzumab. The ZCEH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of combined anti-tumor of trastuzumab and an oxidative stress inducer. As a safe and effective tumor treatment strategy, the ZCEH has huge clinical transformation potential.

The present invention relates to an antibody-drug conjugate of formula (I) or pharmaceutically acceptable salt, solvate or stereoisomer thereof, as well as to intermediates, to pharmaceutical compositions, to methods for treating diseases or disorders and the use of said compounds as pharmaceutical products for treating diseases or disorders.

The invention provides inhalable microgel with enzyme responsiveness and a preparation method of the inhalable microgel, and belongs to the technical field of inhalation type preparations. Microgel constructed by a cross-linking agent with MMP2 enzyme responsiveness serves as a carrier, nintedanib and trastuzumab are jointly entrapped, enzyme-triggered targeted release of the medicine at the pulmonary fibrosis part is achieved through inhalation administration, and the curative effect is synergistically enhanced; the preparation method of the microgel comprises the following steps: preparing nintedanib lipidosome, and reducing disulfide bonds of trastuzumab; the preparation method comprises the following steps: preparing a nintedanib lipidosome and trastuzumab through a sulfydryl-maleimide reaction to obtain a solution containing free sulfydryl, connecting the nintedanib lipidosome and trastuzumab through the sulfydryl-maleimide reaction, mixing the nintedanib lipidosome solution connected with trastuzumab with a cross-linking agent prepared from CPVGLIDC and 4-arm polyethylene glycol maleimide according to a molar ratio of 1: 1, and preparing microgel through a water-in-oil emulsification method; and finally, carrying out gradient centrifugal screening to obtain microgels with three particle sizes. Nintedanib and trastuzumab synergistically enhance the anti-pulmonary fibrosis effect, and the effect is better than that of single-drug treatment.

The present application belongs to the technical field of computer and image processing, and particularly relates to a gastric cancer pathological image classification method and system based on HER2 gene detection, aiming to solve the problem that the prior art cannot accurately classify gastric cancer pathological images, thereby failing to effectively assist doctors in predicting the curative effect of trastuzumab treatment for patients. The present application comprises: obtaining a gastric digital pathological section image of a gastric cancer patient; performing region extraction and segmentation operation to obtain a plurality of image blocks with a set pixel size and containing a set tissue type; performing data enhancement normalization and data division of the image blocks to obtain a training image package; performing network iterative training through the training image package to obtain a gastric cancer pathological image classification model; and classifying the real-time obtained gastric digital pathological section image of the patient through the gastric cancer pathological image classification model. The present application realizes accurate classification of gastric cancer pathological images, thereby assisting doctors in effectively predicting the curative effect of trastuzumab treatment for patients.

Described herein methods of using antigen-binding constructs to treat HER2+ tumors in a subject such as breast, lung, or head and neck tumors. In some aspects, the tumor volume in the subject after receiving at least seven doses of the antigen binding construct is less than the tumor volume of a control subject receiving an equivalent amount of trastuzumab. In some aspects, the survival of the subject receiving the antigen binding construct is increased as compared to a control subject receiving an equivalent amount of a non-specific control antibody or as compared to a control subject not receiving treatment.

Systems and methods for producing liposomes, including control liposomes and immunoliposomes targeting breast cancer are provided. Systems and methods for treating breast cancer, using targeted immunoliposomes produced according to various methods are also disclosed herein. For example, trastuzumab-conjugated immunoliposomes may be used to deliver chemotherapeutic agents to breast cancer tissues for the treatment of breast cancer. Systems and methods for actuating liposomes using ultrasound are also disclosed, such as systems and methods for actuating trastuzumab-conjugated liposomes accumulated in breast cancer tissues for the treatment of breast cancer.

Disclosed are an rk polypeptide radiopharmaceutical targeting HER2, and a preparation method therefor. The rk polypeptide radiopharmaceutical comprises an rk polypeptide dimer and a radionuclide, wherein the radionuclide marks the rk polypeptide dimer by means of a chelating agent, the rk polypeptide dimer is a polypeptide dimer formed by connecting PKM and rk polypeptide monomers and then dimerizing two rk polypeptide monomers connected to the PKM; each rk polypeptide monomer is a D-type amino acid linear eight-membered polypeptide, and the sequence of the rk polypeptide monomer is as follows: Arg-Asn-Trp-Glu-Leu-Arg-Leu-Lys; and the PKM represents a pharmacokinetic modifying molecule. The radiopharmaceutical is used for imaging diagnosis of HER2-positive tumor patients, and medication guidance and real-time therapeutic effect monitoring of patients treated by monoclonal antibodies of the anti-cancer drug trastuzumab.

The application discloses an antibody functionalized nano delivery system MET@Fe3O4@BSA-TZ and a preparation method and application thereof. A four-iron oxide (Fe3O4) nanoparticle having a chemical dynamic therapy (CDT), a photothermal therapy (PTT) and an iron death induction capacity is prepared by using a one-step hydrothermal synthesis method as a nano carrier core, metformin (MET) capable of improving a tumor microenvironment and enhancing NK cell infiltration is loaded by physical adsorption, bovine serum albumin (BSA) is wrapped on the surface to improve biocompatibility and reduce the clearance efficiency of the body, and finally, trastuzumab (TZ) is covalently coupled and modified to realize specific targeting of Her-2 positive breast cancer cells, so that a multifunctional nano delivery system MET@Fe3O4@BSA-TZ (MFBT) is successfully constructed. In-vivo and in-vitro experiments prove that the MFBT can significantly inhibit the proliferation of drug-resistant tumors, improve the immunosuppressive microenvironment of the tumor and improve the anti-tumor treatment effect, and is safe and reliable, thereby providing a new and efficient treatment strategy for the precise treatment of Her-2 positive breast cancer.

Provided are a bispecific antibody against human HER2 / CCR4 and a use thereof. Provided is a bispecific antibody capable of simultaneously targeting an HER2 target and a CCR4 target. The bispecific antibody comprises a first antigen-binding region, a second antigen-binding region and an Fc domain, wherein the first antigen-binding region has an HER2-binding activity, the second antigen-binding region has a CCR4-binding activity, and the Fc domain is an Fc domain of a trastuzumab monoclonal antibody. The bispecific antibody can bind to HER2 with a high specificity and a high affinity, and bind to CCR4 with a high specificity and a relatively low affinity. The bispecific antibody promotes effector cells to kill tumor cells and Treg cells in the tumor microenvironment, and effectively avoids the depletion of Treg cells in the peripheral blood caused by CCR4 monoclonal antibodies, thereby having a good anti-cancer activity and a higher safety.